Catalyst Pharmaceuticals

Catalyst Pharmaceuticals:
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSEĀ® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA") and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase III, Phase l or ll
Disease Space
Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
Suite 801
Coral Gables, FL 33134
United States
More info:
My account:
Company Participants at Solebury Trout 1x1 Management Access Event 2022
- Jeff Del Carmen, CCO
- Mary Coleman, Vice President, Investor Relations
- Patrick J McEnany, Chairman/President/CEO/Co-Founder
- Steven Miller, Chief Operating Officer & Chief Scientific Officer
Top 10 Holders of Catalyst Pharmaceuticals, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
BlackRock Fund Advisors | 10.68 | 11,323,870 | 132.38 | 13F | 6/30/23 |
State Street Corp. | 8.91 | 9,453,077 | 110.51 | 13F | 6/30/23 |
Deerfield Management Co. LP | 7.72 | 8,192,000 | 95.76 | 13F | 6/30/23 |
Vanguard Group, Inc. (Subfiler) | 6.23 | 6,611,102 | 77.28 | 13F | 6/30/23 |
BlackRock Institutional Trust Co. NA | 2.82 | 2,986,589 | 34.91 | 13F | 6/30/23 |
Dimensional Fund Advisors LP | 2.33 | 2,472,410 | 28.90 | 13F | 6/30/23 |
The Vanguard Group, Inc. | 1.89 | 2,012,353 | 23.52 | Funds | 8/31/23 |
Geode Capital Management LLC | 1.82 | 1,926,415 | 22.52 | 13F | 6/30/23 |
Jacobs Levy Equity Management, Inc. | 1.25 | 1,321,281 | 15.45 | 13F | 6/30/23 |
Invesco Capital Management LLC | 1.14 | 1,210,264 | 14.15 | 13F | 6/30/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.